SynthesisGastroenterology2020
Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Synthesis in Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Artificial intelligence-enabled histology exhibits comparable accuracy to pathologists in assessing histological remission in ulcerative colitis: a systematic review, meta-analysis, and meta-regression.Journal of Crohn's & colitis · 2025Pooled it
- Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis.BMC gastroenterology · 2022Pooled it
- Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.Journal of Crohn's & colitis · 2026Trial
- Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis.Med (New York, N.Y.) · 2025Trial
- Qingchang suppositry induced remission in patients with mild-to-moderate ulcerative proctitis: a multicenter, prospective, randomized, parallel-controlled clinical trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Trial
- Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.Journal of Crohn's & colitis · 2023Trial
- Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.Journal of gastroenterology · 2023Trial
- The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis.Alimentary pharmacology & therapeutics · 2026Article
- Advanced endoscopy and artificial intelligence-enabled vascular healing for ulcerative colitis: promising frontiers or mere mirage?Clinical endoscopy · 2026Review
- Selective IL-23 inhibitors in ulcerative colitis: current evidence and perspectives for multimodal personalized treatment: a narrative review.Journal of gastroenterology · 2026Review
- Standardized, repeatable ulcerative colitis histology scoring and endpoint assessment using an automated, foundation model-based tool.medRxiv : the preprint server for health sciences · 2026Article
- Diagnostic efficacy of pan-immune inflammation value for ulcerative colitis activity: a study based on multi-indicator comparison and diagnostic grey zone validation.BMC gastroenterology · 2026Article
- Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a long-term follow-up of the randomized RIVETING trial.Crohn's & colitis 360 · 2026Article
- A deeper quiet: Tofacitinib and the potential of endo-histologic remission.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Epithelial SLPI expression in severe inflammatory bowel disease relates to high IL-17 and neutrophil programming.JCI insight · 2026Article
- Integrated Assessment of Intestinal Barrier Function and Microscopic Inflammation Using Confocal Laser Endomicroscopy for Relapse Prediction in Ulcerative Colitis.United European gastroenterology journal · 2026Article
- Observational
- Treat-to-Target in Ulcerative Colitis: How Soon Is Now?Journal of clinical medicine · 2026Article
- Disease Clearance Reduces the Risk of Adverse Outcomes and Provides Additional Benefit Beyond Individual Clinical, Endoscopic, or Histological Remission in Ulcerative Colitis.Journal of clinical medicine · 2026Article
- Leveraging patient-reported outcomes and serum markers to predict active ulcerative colitis: a multicenter cohort.Frontiers in medicine · 2026Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND &
aimsClinical remission, defined by a composite of patient reported outcomes and Mayo endoscopy subscore (MES) 0 or 1 is a recommended treatment target in patients with ulcerative colitis (UC). We estimated whether incorporating more rigorous remission definitions, of endoscopic remission (MES 0) and histologic remission, affects risk of relapse.
methodsThrough a systematic review, we identified cohort studies in adults with UC in clinical remission that reported a minimum 12-month risk of clinical relapse, based on MES (0 vs 1) and/or histologic disease activity, in patients with endoscopic remission. Using random effects meta-analysis, we calculated relative and absolute risk of clinical relapse in patients with UC achieving different treatment targets.
resultsIn a meta-analysis of 17 studies that included 2608 patients with UC in clinical remission, compared to patients achieving MES 1, patients achieving MES 0 had a 52% lower risk of clinical relapse (relative risk, 0.48; 95% CI, 0.37-0.62). The median 12-month risk of clinical relapse in patients with MES 1 was 28.7%; the estimated annual risk of clinical relapse in patients with MES 0 was 13.7% (95% CI, 10.6-17.9). In a meta-analysis of 10 studies in patients in endoscopic remission (MES 0), patients who achieved histologic remission had a 63% lower risk of clinical relapse vs patients with persistent histologic activity (relative risk, 0.37; 95% CI, 0.24-0.56). Estimated annual risk of clinical relapse in who achieved achieving histologic remission was 5.0% (95% CI, 3.3-7.7).
conclusionsIn a systematic review and meta-analysis of patients with UC in clinical remission, we observed that patients achieving more rigorous treatment endpoints (endoscopic and histologic remission) have a substantially lower risk of clinical relapse compared with patients achieving clinical remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.